Lenvaxen 10 mg (Capsule)
Unit Price: ৳ 990.00 (1 x 30: ৳ 29,700.00)
Strip Price: ৳ 29,700.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Lenvatinib mesylate |
| Company | Everest pharmaceuticals ltd |
| Also available as |
Indications
- Differentiated Thyroid Cancer
- Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Endometrial Carcinoma
Pharmacology
- Kinase inhibitor
- Inhibits VEGF receptors
- Inhibits FGF receptors
- Inhibits PDGFR
- Inhibits KIT
- Antiproliferative activity in hepatocellular carcinoma cell lines
Absorption
Time to peak plasma concentration 1-4 hours post-dose
Distribution
98-99% binding to human plasma proteins, blood-to-plasma concentration ratio 0.59-0.61
Metabolism
Mainly enzymatic and non-enzymatic processes
Elimination
- 64% elimination in feces
- 25% elimination in urine
- Terminal elimination half-life approximately 28 hours
Dosage
- Recommended for Differentiated Thyroid Cancer: 24 mg orally once daily
- Recommended for Renal Cell Carcinoma: 18 mg in combination with 5 mg Everolimus orally once daily
- Recommended for Hepatocellular Carcinoma: 12 mg for patients greater than or equal to 60 kg or 8 mg for patients less than 60 kg once daily
- Recommended for Endometrial Carcinoma: 20 mg orally once daily in combination with Pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks
Administration
Capsules can be swallowed whole or dissolved in a small glass of liquid
Interaction
Avoid coadministration with drugs that prolong the QT interval
Contraindications
Known hypersensitivity to Lenvatinib or any component of the formulation
Side Effects
- Hypertension
- Cardiac dysfunction
- Arterial thromboembolic events
- Hepatotoxicity
- Renal failure and impairment
- Diarrhea
- Fistula formation and gastrointestinal perforation
- QT Interval Prolongation
- Hypocalcemia
- Reversible posterior leukoencephalopathy syndrome
- Hemorrhagic events
- Impairment of thyroid stimulating hormone suppression/thyroid dysfunction
- Wound healing complications
Pregnancy & Lactation
- Can cause embryo-fetal harm
- Use effective contraception during treatment
- Discontinue breastfeeding during treatment
Precautions & Warnings
- Hypertension control
- Monitor for cardiac dysfunction
- Arterial thromboembolic events
- Monitor liver function
- Monitor for renal failure or impairment
- Monitor for proteinuria
- Promptly initiate management of diarrhea
- Monitor and correct electrolyte abnormalities
- Monitor and treat hypothyroidism
- Wound healing complications
Use in Special Populations
- Dosage modifications for severe renal impairment
- Dosage modifications for severe hepatic impairment
- Not established for pediatric use
Overdose Effects
Not expected to be dialyzable, death occurred at a single dose of 120 mg
Storage Conditions
Store below 30°C in a dry place, protect from light, keep out of the reach of children